Novartis (NOVN SW) - Q2 2026 (USD): Net Revenue 14.4bln (exp. 14.1bln), Core EPS 2.41 (exp. 2.20), Operating income 4.75bln (prev. 4.86bln Y/Y), Net income 3.26bln (prev. 4.02bln Y/Y), backs FY26 view

Novartis reported a strong Q2 2026, beating revenue and EPS expectations, indicating solid underlying performance despite a year-over-year decline in net income and operating income.

Newsquawk StaffPublished On the live feed at 1 more headline followed before this page went public
Newsquawk headlinesUTC

Newsquawk Daily European Opening News - 21st July 2026

UK government to remove VAT on electricity bills from October 1st, funded by cancellation of Digital ID programme, as part of new tax cut measures

Novartis (NOVN SW) - Q2 2026 (USD): Net Revenue 14.4bln (exp. 14.1bln), Core EPS 2.41 (exp. 2.20), Operating income 4.75bln (prev. 4.86bln Y/Y), Net income 3.26bln (prev. 4.02bln Y/Y), backs FY26 view

[EARNINGS PREVIEW] Novartis and Roche to kick off Pharma earnings.

Iran drone attack hit 3 US bases in Kuwait

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

Sales (USD):

  • Entresto 1.18bln (exp. 1.29bln)
  • Cosentyx 1.82bln (exp. 1.14bln)

FY outlook:

  • Expects net sales to grow low single-digit.
  • Expects core operating income to decline low single-digit.

CEO:

  • “Novartis delivered a solid second quarter, returning to sales growth driven by continued momentum from Kisqali, Kesimpta, Scemblix and Pluvicto."
  • "We are on track for multiple  important readouts ahead in the second half, and remain on track to deliver our full-year guidance and mid-term outlook.”
Context

The results suggest confidence in their growth trajectory, supported by the CEO's remarks on ongoing momentum from key products, which may stabilize market sentiment and keep full-year guidance intact. This could positively influence investor perception and stock performance, particularly in the pharmaceuticals sector.

Related headlines

The whole workspace, free to try.

Try it free